Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LIXT
#3813
Lixte Biotechnology Holdings, Inc. Common Stock
2.9
0
-2.68%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-2.68%
Monatliche Änderung
-15.20%
6 month change
-15.20%
Jahresänderung
+110.14%
Vorheriger Schlusskurs
2.9
8
Open
2.8
9
Bid
Ask
Low
2.8
5
High
2.9
4
Volumen
20
Märkte
Aktien
Gesundheitswesen
LIXT
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
Nachrichten
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary
LIXTE expands clinical trial for ovarian cancer treatment
Lixte Biotechnology stock falls after $4.3 million direct offering
Spartan Capital acts as placement agent in Lixte’s $4.3 million offering
Lixte Biotechnology stock falls after $4.3 million direct offering
Lixte Biotechnology raises $4.3 million in registered direct offering
Lixte Biotechnology shareholders approve board nominees and stock plan amendment
Lixte Biotechnology stock falls after acquiring UK-based Liora
LIXTE Biotechnology acquires UK-based proton therapy developer Liora
Earlyworks shareholders reject share issuance for acquisition, approve new directors and warrants
BOCA RATON - Lixte Biotechnology refreshes leadership and diversifies assets
LIXTE Biotechnology announces leadership changes and $5 million funding